Logo image of EXEL

EXELIXIS INC (EXEL) Stock Fundamental Analysis

USA - NASDAQ:EXEL - US30161Q1040 - Common Stock

39.21 USD
-0.82 (-2.05%)
Last: 10/16/2025, 8:00:02 PM
39.21 USD
0 (0%)
After Hours: 10/16/2025, 8:00:02 PM
Fundamental Rating

8

We assign a fundamental rating of 8 out of 10 to EXEL. EXEL was compared to 536 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making EXEL a very profitable company, without any liquidiy or solvency issues. EXEL is evaluated to be cheap and growing strongly. This does not happen too often! These ratings could make EXEL a good candidate for value and growth and quality investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year EXEL was profitable.
In the past year EXEL had a positive cash flow from operations.
In the past 5 years EXEL has always been profitable.
In the past 5 years EXEL always reported a positive cash flow from operatings.
EXEL Yearly Net Income VS EBIT VS OCF VS FCFEXEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

EXEL's Return On Assets of 22.49% is amongst the best of the industry. EXEL outperforms 97.01% of its industry peers.
EXEL has a better Return On Equity (29.62%) than 97.20% of its industry peers.
With an excellent Return On Invested Capital value of 25.22%, EXEL belongs to the best of the industry, outperforming 98.32% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for EXEL is below the industry average of 15.49%.
The last Return On Invested Capital (25.22%) for EXEL is above the 3 year average (10.78%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 22.49%
ROE 29.62%
ROIC 25.22%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
EXEL Yearly ROA, ROE, ROICEXEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 150

1.3 Margins

EXEL's Profit Margin of 27.01% is amongst the best of the industry. EXEL outperforms 96.08% of its industry peers.
EXEL's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 33.71%, EXEL belongs to the top of the industry, outperforming 97.57% of the companies in the same industry.
EXEL's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 96.59%, EXEL belongs to the top of the industry, outperforming 95.90% of the companies in the same industry.
EXEL's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 33.71%
PM (TTM) 27.01%
GM 96.59%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
EXEL Yearly Profit, Operating, Gross MarginsEXEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

9

2. Health

2.1 Basic Checks

EXEL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
EXEL has less shares outstanding than it did 1 year ago.
The number of shares outstanding for EXEL has been reduced compared to 5 years ago.
EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
EXEL Yearly Shares OutstandingEXEL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
EXEL Yearly Total Debt VS Total AssetsEXEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

EXEL has an Altman-Z score of 11.85. This indicates that EXEL is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 11.85, EXEL belongs to the top of the industry, outperforming 85.26% of the companies in the same industry.
EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 11.85
ROIC/WACC2.69
WACC9.39%
EXEL Yearly LT Debt VS Equity VS FCFEXEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B

2.3 Liquidity

A Current Ratio of 3.51 indicates that EXEL has no problem at all paying its short term obligations.
EXEL has a Current ratio (3.51) which is comparable to the rest of the industry.
A Quick Ratio of 3.44 indicates that EXEL has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.44, EXEL is in line with its industry, outperforming 41.60% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.51
Quick Ratio 3.44
EXEL Yearly Current Assets VS Current LiabilitesEXEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

8

3. Growth

3.1 Past

EXEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 67.74%, which is quite impressive.
EXEL shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.65% yearly.
EXEL shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.73%.
The Revenue has been growing by 17.51% on average over the past years. This is quite good.
EPS 1Y (TTM)67.74%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%-15.58%
Revenue 1Y (TTM)10.73%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%-10.82%

3.2 Future

Based on estimates for the next years, EXEL will show a very strong growth in Earnings Per Share. The EPS will grow by 22.20% on average per year.
The Revenue is expected to grow by 10.31% on average over the next years. This is quite good.
EPS Next Y30.7%
EPS Next 2Y25.58%
EPS Next 3Y26.34%
EPS Next 5Y22.2%
Revenue Next Year7.16%
Revenue Next 2Y9.78%
Revenue Next 3Y11.43%
Revenue Next 5Y10.31%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
EXEL Yearly Revenue VS EstimatesEXEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
EXEL Yearly EPS VS EstimatesEXEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 18.85, EXEL is valued on the expensive side.
Based on the Price/Earnings ratio, EXEL is valued cheaply inside the industry as 95.34% of the companies are valued more expensively.
EXEL's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.29.
A Price/Forward Earnings ratio of 13.44 indicates a correct valuation of EXEL.
Compared to the rest of the industry, the Price/Forward Earnings ratio of EXEL indicates a rather cheap valuation: EXEL is cheaper than 95.71% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.85. EXEL is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 18.85
Fwd PE 13.44
EXEL Price Earnings VS Forward Price EarningsEXEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, EXEL is valued cheaply inside the industry as 95.71% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of EXEL indicates a rather cheap valuation: EXEL is cheaper than 96.83% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 14
EV/EBITDA 11.69
EXEL Per share dataEXEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

EXEL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of EXEL may justify a higher PE ratio.
EXEL's earnings are expected to grow with 26.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.61
PEG (5Y)1.49
EPS Next 2Y25.58%
EPS Next 3Y26.34%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EXEL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXELIXIS INC

NASDAQ:EXEL (10/16/2025, 8:00:02 PM)

After market: 39.21 0 (0%)

39.21

-0.82 (-2.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-28 2025-07-28/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners96.89%
Inst Owner Change-0.04%
Ins Owners2.23%
Ins Owner Change-2.59%
Market Cap10.56B
Analysts76.92
Price Target45.2 (15.28%)
Short Float %6.68%
Short Ratio5.78
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.5%
Min EPS beat(2)13.99%
Max EPS beat(2)49.01%
EPS beat(4)4
Avg EPS beat(4)21.76%
Min EPS beat(4)10.66%
Max EPS beat(4)49.01%
EPS beat(8)6
Avg EPS beat(8)17.86%
EPS beat(12)9
Avg EPS beat(12)18.64%
EPS beat(16)12
Avg EPS beat(16)38.79%
Revenue beat(2)1
Avg Revenue beat(2)3.15%
Min Revenue beat(2)-3.02%
Max Revenue beat(2)9.31%
Revenue beat(4)2
Avg Revenue beat(4)3.21%
Min Revenue beat(4)-3.02%
Max Revenue beat(4)9.31%
Revenue beat(8)3
Avg Revenue beat(8)4.17%
Revenue beat(12)5
Avg Revenue beat(12)2.6%
Revenue beat(16)7
Avg Revenue beat(16)2.9%
PT rev (1m)-1.52%
PT rev (3m)7.26%
EPS NQ rev (1m)-0.95%
EPS NQ rev (3m)-0.22%
EPS NY rev (1m)2.3%
EPS NY rev (3m)2.93%
Revenue NQ rev (1m)-0.11%
Revenue NQ rev (3m)-0.66%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)-0.76%
Valuation
Industry RankSector Rank
PE 18.85
Fwd PE 13.44
P/S 4.73
P/FCF 14
P/OCF 13.67
P/B 5.19
P/tB 5.36
EV/EBITDA 11.69
EPS(TTM)2.08
EY5.3%
EPS(NY)2.92
Fwd EY7.44%
FCF(TTM)2.8
FCFY7.14%
OCF(TTM)2.87
OCFY7.31%
SpS8.28
BVpS7.55
TBVpS7.32
PEG (NY)0.61
PEG (5Y)1.49
Profitability
Industry RankSector Rank
ROA 22.49%
ROE 29.62%
ROCE 32.1%
ROIC 25.22%
ROICexc 38.09%
ROICexgc 39.72%
OM 33.71%
PM (TTM) 27.01%
GM 96.59%
FCFM 33.81%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
ROICexc(3y)19.16%
ROICexc(5y)19.43%
ROICexgc(3y)20.04%
ROICexgc(5y)20.66%
ROCE(3y)13.72%
ROCE(5y)11.89%
ROICexcg growth 3Y9.55%
ROICexcg growth 5Y2.44%
ROICexc growth 3Y10.88%
ROICexc growth 5Y3.03%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
F-Score8
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 60.32%
Cap/Sales 0.81%
Interest Coverage 250
Cash Conversion 98.79%
Profit Quality 125.2%
Current Ratio 3.51
Quick Ratio 3.44
Altman-Z 11.85
F-Score8
WACC9.39%
ROIC/WACC2.69
Cap/Depr(3y)129.54%
Cap/Depr(5y)238.73%
Cap/Sales(3y)1.75%
Cap/Sales(5y)2.56%
Profit Quality(3y)151.16%
Profit Quality(5y)151.8%
High Growth Momentum
Growth
EPS 1Y (TTM)67.74%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%-15.58%
EPS Next Y30.7%
EPS Next 2Y25.58%
EPS Next 3Y26.34%
EPS Next 5Y22.2%
Revenue 1Y (TTM)10.73%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%-10.82%
Revenue Next Year7.16%
Revenue Next 2Y9.78%
Revenue Next 3Y11.43%
Revenue Next 5Y10.31%
EBIT growth 1Y86.61%
EBIT growth 3Y34.01%
EBIT growth 5Y13.3%
EBIT Next Year41.83%
EBIT Next 3Y24.19%
EBIT Next 5Y1.16%
FCF growth 1Y108.65%
FCF growth 3Y25.89%
FCF growth 5Y5.48%
OCF growth 1Y98.36%
OCF growth 3Y20.43%
OCF growth 5Y5.84%